Years ago, ischemic stroke was regarded as a model disease for the development of neuroprotective therapies by the pharmacological industry. Results were disappointing. There are still no treatments available allowing the rescue of brain tissue once a stroke has occurred. Study failure is not only a problem in the stroke field. In other neurodegenerative conditions and in non-degenerative brain disorders, progress in drug development was also rather scarce until recently. An important factor in drug failure is the blood—brain barrier, which expresses active transporters that eliminate drugs from the brain. These transporters exhibit strong variations between different animals, which make it difficult to predict brain concentrations of drugs over species barriers. This paper claims that more detailed knowledge about:
(1) the biology of blood—brain barrier transporters; (2) their regulation in brain disease,
(3) the affinity of transporters to candidate drugs; and (4) the accumulation of drugs in brain tissue is needed for the overall success of clinical trials to be improved. An alternative strategy could be the use of disease-modifying treatments that do not have to enter the brain to exert their function. As such, restorative and anti-inflammatory strategies acting at the blood—brain interface might gain therapeutic potential in the future.
Abbott, N.J., Rönnbäck, L. and Hansson, E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier, Nat Rev Neurosci7: 41-53.
2.
Agrawal, M., Abraham, J., Balis, F.M., Edgerly, M., Stein, W.D., Bates, S. et al. (2003) Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576, Clin Cancer Res9: 650-656.
3.
Albers, G.W., Goldstein, L.B., Hall, D. and Lesko, L.M. (2001) Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial, JAMA286: 2673-2682.
4.
Bacigaluppi, M. and Hermann, D.M. (2008) New targets of neuroprotection in ischemic stroke , Scientific World Journal8: 698-712.
5.
Bacigaluppi, M., Pluchino, S., Martino, G., Kilic, E. and Hermann, D.M. (2008) Neural stem/precursor cells for the treatment of ischemic stroke, J Neurol Sci265: 73-77.
6.
Badan, I., Buchhold, B., Hamm, A., Gratz, M., Walker, L.C., Platt, D. et al. (2003) Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery, J Cereb Blood Flow Metab23: 845-854.
7.
Baltes, S., Gastens, A.M., Fedrowitz, M., Potschka, H., Kaever, V. and Löscher, W. (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse p-glycoprotein , Neuropharmacology52: 333-346.
8.
Bauer, B., Hartz, A.M., Lucking, J.R., Yang, X., Pollack, G.M. and Miller, D.S. (2008) Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and phase-II metabolising enzyme, GSTpi, at the blood-brain barrier, J Cereb Blood Flow Metab28: 1222-1234.
9.
Begley, D.J. (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities, Pharmacol Ther104: 29-45.
10.
Bolhuis, H., van Veen, H.W., Molenaar, D., Poolman, B., Driessen, A.J. and Konings, W.N. (1996) Multidrug resistance in lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane, EMBO J15: 4239-4245.
11.
Busch, E., Krüger, K., Allegrini, P.R., Kerskens, C.M., Gyngell, M.L., Hoehn-Berlage, M. et al. (1998) Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance and biochemical imaging, J Cereb Blood Flow Metab18: 407-418.
12.
Comerford, K.M., Wallace, T.J., Karhausen, J., Louis, N.A., Montalto, M.C. and Colgan, S.P. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene, Cancer Res62: 3387-3394.
13.
Cotzias, G.C., Papavasiliou, P.S. and Gellene, R. (1969) Modification of Parkinsonism - chronic treatment with L-dopa, N Engl J Med280: 337-345.
14.
Davis, S.M., Lees, K.R., Albers, G.W., Diener, H.C., Markabi, S., Karlsson, G. and Norris, J. (2000) Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke31: 347-354.
15.
Dénes, A., Ferenczi, S., Halász, J., Környei, Z. and Kovács, K.J. (2008) Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse, J Cereb Blood Flow Metab Jun 25.
16.
Dimitrijevic, O.B., Stamatovic, S.M., Keep, R.F. and Andjelkovic, A.V. (2007) Absence of the chemokine receptor CCR2 protects against cerebral ischemia/ reperfusion injury in mice , Stroke38: 1345-1353.
17.
Donnan, G.A. (2008) The 2007 Feinberg Lecture: a new road map for neuroprotection , Stroke39: 242.
18.
Endres, M., Namura, S., Shimizu-Sasamata, M., Waeber, C., Zhang, L., Gómez-Isla, T. et al. (1998) Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family, J Cereb Blood Flow Metab18: 238-247.
19.
Felix, R.A. and Barrand, M.A. (2002) P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress, J Neurochem80: 64-72.
20.
Fellay, J., Marzolini, C., Meaden, E.R., Back, D.J., Buclin, T., Chave, J.P. et al. (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study, Lancet359: 30-36.
21.
Festoff, B.W., Suo, Z. and Citron, B.A. (2003) Prospects for the pharmacotherapy of amyotrophic lateral sclerosis: old strategies and new paradigms for the third millennium , CNS Drugs17: 699-717.
22.
Feuerstein, G.Z., Zaleska, M.M., Krams, M., Wang, X., Day, M., Rutkowski, J.L. et al. (2008) Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke, J Cereb Blood Flow Metab28: 217-219.
23.
Garrigues, A., Nugier, J., Orlowski, S. and Ezan, E. (2002) A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein, Anal Biochem305: 106-114.
24.
Gennuso, F., Fernetti, C., Tirolo, C., Testa, N., L'Episcopo, F., Caniglia, S. et al. (2004) Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1), Proc Natl Acad Sci USA101: 2470-2475.
25.
Gerrard, G., Payne, E., Baker, R.J., Jones, D.T., Potter, M., Prentice, H.G. et al. (2004) Clinical effects and p-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine, Haematologica89: 782-790.
26.
Gottesman, M.M., Fojo, T. and Bates, S.E. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer2: 48-58.
27.
Hacke, W., Donnan, G., Fieschi, C., Kaste, M., von Kummer, R., Broderick, J.P. et al. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , Lancet363: 768-774.
28.
Hagenbuch, B. and Meier, P.J. (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties, Pflugers Arch447: 653-665.
29.
Hata, R., Maeda, K., Hermann, D., Mies, G. and Hossmann, K.A. (2000a) Dynamics of regional brain metabolism and gene expression after middle cerebral artery occlusion in mice, J Cereb Blood Flow Metab20: 306-315.
30.
Hata, R., Maeda, K., Hermann, D., Mies, G. and Hossmann, K.A. (2000b) Evolution of brain infarction after transient focal cerebral ischemia in mice, J Cereb Blood Flow Metab20: 937-946.
31.
Hermann, D.M., Kilic, E., Hata, R., Hossmann, K.A. and Mies, G. (2001) Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice . Neuroscience104: 947-955.
32.
Hermann, D.M. (2007) Biodistribution processes as underestimated confounders in translational stroke research, Curr Med Chem14: 3179-3184.
33.
Hermann, D.M. and Bassetti, C.L. (2007a) Implications of ATP-binding cassette transporters for brain pharmacotherapies, Trends Pharmacol Sci28: 128-134.
34.
Hermann, D.M. and Bassetti, C.L. (2007b) Neuroprotection in the SAINT-II aftermath, Ann Neurol62: 677-678.
35.
Hermann, D.M., Kilic, E., Hata, R., Hossmann, K.A. and Mies, G. (2001) Relationship between metabolic dysfunctions, gene responses and delayed cell death after mild focal cerebral ischemia in mice , Neuroscience104: 947-955.
36.
Hermann, D.M., Kilic, E., Spudich, A., Krämer, S.D., Wunderli-Allenspach, H. and Bassetti, C.L. (2006) Role of drug efflux carriers in the healthy and diseased brain, Ann Neurol60: 489-498.
37.
Higgins, C.F. and Linton, K.J. (2004) The ATP switch model for ABC transporters, Nat Struct Mol Biol11: 918-926.
38.
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H.P., Brockmoller, J., Johne, A. et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc Natl Acad Sci USA97: 3473-3478.
39.
Hossmann, K.A. (1994) Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised, Brain Pathol4: 23-36.
40.
Hossmann, K.A. (2006) Pathophysiology and therapy of experimental stroke , Cell Mol Neurobiol26: 1057-1083.
41.
Kemper, E.M., van Zandbergen, A.E., Cleypool, C., Mos, H.A., Boogerd, W., Beijnen, J.H. et al. (2003) Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein, Clin Cancer Res9: 2849-2855.
42.
Kieburtz, K. and Ravina, B. (2007) Why hasn't neuroprotection worked in Parkinson's disease? Nat Clin Pract Neurol3: 240-241.
43.
Kilic, E., Hermann, D.M. and Hossmann, K.A. (1998) A reproducible model of thromboembolic stroke in mice, Neuroreport9: 2967-2970.
44.
Kilic, E., Hermann, D.M. and Hossmann, K.A. (2000) Recombinant tissue-plasminogen activator-induced thrombolysis after cerebral thromboembolism in mice, Acta Neuropathol99: 219-222.
45.
Kilic, U., Kilic, E., Reiter, R.J., Bassetti, C.L. and Hermann, D.M. (2005) Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice, J Pineal Res38: 67-71.
46.
Kilic, Ü., Kilic, E., Järve, A., Guo, Z., Spudich, A., Bieber, K. et al. (2006a) Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways, J Neurosci26: 12439-12446.
47.
Kilic, E., Kilic, Ü., Wang, Y., Bassetti, C.L., Marti, H.H. and Hermann, D.M. (2006b) The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia, FASEB J20: 1185-1187.
48.
Kilic, Ü., Kilic, E., Matter, C.M., Bassetti, C.L. and Hermann, D.M. (2008a) TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration, Neurobiol Dis31: 33-40.
49.
Kilic, E., Kilic, Ü., Bacigaluppi, M., Guo, Z., Abdallah, N.B., Wolfer, D.P., et al. (2008b) Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice, J Pineal Res45: 142-148.
50.
Kornbluth, S. and White, K. (2005) Apoptosis in Drosophila: neither fish nor fowl (nor man, nor worm), J Cell Sci118: 1779-1787.
51.
Kuppens, I.E., Breedveld, P., Beijnen, J.H. and Schellens, J.H. (2005) Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application, Cancer Invest23: 443-464.
52.
Kusuhara, H. and Sugiyama, Y. (2005) Active efflux across the blood-brain barrier: role of the solute carrier family, NeuroRx2: 73-85.
53.
Lee, Y.J., Maeda, J., Kusuhara, H., Okauchi, T., Inaji, M., Nagai, Y. et al. (2006) In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil, J Pharmacol Exp Ther316: 647-653.
54.
Linker, R.A., Weller, C., Lühder, F., Mohr, A., Schmidt, J., Knauth, M. et al. (2008) Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations, Exp Neurol211: 397-406.
55.
Livingston, S., Villamater, C., Sakata, Y. and Pauli, L.L. (1967) Use of carbamazepine in epilepsy. Results in 87 patients, JAMA200: 204-208.
56.
Longa, E.Z., Weinstein, P.R., Carlson, S. and Cummins, R. (1989) Reversible middle cerebral artery occlusion without craniectomy in rats, Stroke20: 84-91.
57.
Löscher, W. and Potschka, H. (2005) Drug resistance in brain diseases and the role of drug efflux transporters, Nat Rev Neurosci6: 591-602.
58.
Martino, G. and Pluchino, S. (2006) The therapeutic potential of neural stem cells , Nat Rev Neurosci7: 395-406.
59.
Marzolini, C., Paus, E., Buclin, T. and Kim, R.B. (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin Pharmacol Ther75: 13-33.
60.
Mies, G., Kohno, K. and Hossmann, K.A. (1993) MK-801, a glutamate antagonist, lowers flow threshold for inhibition of protein synthesis after middle cerebral artery occlusion of rat, Neurosci Lett155: 65-68.
61.
Mies, G., Kohno, K. and Hossmann, K.A. (1994) Prevention of periinfarct direct current shifts with glutamate antagonist NBQX following occlusion of the middle cerebral artery in the rat, J Cereb Blood Flow Metab14: 802-807.
62.
MR Stroke Collaborative GroupPhan, T.G., Donnan, G.A., Davis, S.M. and Byrnes, G. (2006) Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data, Stroke37: 2521-2525.
63.
Murakami, Y., Takamatsu, H., Noda, A., Osoda, K., Ichise, R., Tatsumi, M. et al. (2004) Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent, J Nucl Med45: 1946-1949.
64.
Nasi, M., Borghi, V., Pinti, M., Bellodi, C., Lugli, E., Maffei, S. et al. (2003) MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS17: 1696-1698.
65.
NINDS Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 333: 1581-1587.
66.
O'Collins, V.E., Macleod, M.R., Donnan, G.A., Horky, L.L., van der Worp, B.H. and Howells, D.W. (2006) 1,026 experimental treatments in acute stroke. Ann Neurol59: 467-477.
67.
Petcu, E.B., Sfredel, V., Platt, D., Herndon, J.G., Kessler, C. and Popa-Wagner, A. (2008) Cellular and molecular events underlying the dysregulated response of the aged brain to stroke: a mini-review, Gerontology54: 6-17.
68.
Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med354: 899-910.
69.
Rubin, E.H., de Alwis, D.P., Pouliquen, I., Green, L., Marder, P., Lin, Y. et al. (2002) A phase I trial of a potent p-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies, Clin Cancer Res8: 3710-3717.
70.
Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med354: 911-923.
71.
Sauter, A. and Rudin, M. (1995) Strain-dependent drug effects in rat middle cerebral artery occlusion model of stroke, J Pharmacol Exp Ther274: 1008-1013.
72.
Savitz, S.I. and Fisher, M. (2007) Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials, Ann Neurol61: 396-402.
73.
Savitz, S.I. (2007) A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke, Exp Neurol205: 20-25.
74.
Segura, T., Calleja, S. and Jordan, J. (2008) Recommendations and treatment strategies for the management of acute ischemic stroke, Expert Opin Pharmacother9: 1071-1085.
75.
Sehara, Y., Hayashi, T., Deguchi, K., Zhang, H., Tsuchiya, A., Yamashita, T. et al. (2007) Decreased focal inflammatory response by G-CSF may improve stroke outcome after transient middle cerebral artery occlusion in rats, J Neurosci Res85: 2167-2174.
76.
Sharom, F.J. (2006) Shedding light on drug transport: structure and function of the p-glycoprotein multidrug transporter (ABCB1), Biochem Cell Biol84: 979-992.
77.
Shuaib, A., Lees, K.R., Lyden, P., Grotta, J., Davalos, A., Davis, S.M. et al. (2007) NXY-059 for the treatment of acute ischemic stroke, N Engl J Med357: 562-571.
78.
Sharma, V., Prior, J.L., Belinsky, M.G., Kruh, G.D. and Piwnica-Worms, D. (2005) Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier , J Nucl Med46: 354-364.
79.
Siddiqui, A., Kerb, R., Weale, M.E., Brinkmann, U., Smith, A., Goldstein, D.B. et al. (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1, N Engl J Med348: 1442-1448.
80.
Soontornmalai, A., Vlaming, M.L. and Fritschy, J.M. (2006) Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier, Neuroscience138: 159-169.
81.
Spudich, A., Kilic, E., Xing, H., Kilic, U., Rentsch, K.M., Wunderli-Allenspach et al. ( 2006) Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia, Nat Neurosci9: 487-488.
82.
Stroke Therapy AcademicIndustry Roundtable (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development, Stroke30: 2752-2758.
83.
Stroke Therapy AcademicIndustry Roundtable (2001) Recommendations for clinical trial evaluation of acute stroke therapies, Stroke32: 1598-1606.
84.
Stroke Therapy AcademicIndustry Roundtable (2005) Enhancing the development and approval of acute stroke therapies, Stroke36: 1808-1813.
85.
Thomas, H. and Coley, H.M. (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein, Cancer Control10: 159-165.
86.
Tidefelt, U., Liliemark, J., Gruber, A., Liliemark, E., Sundman-Engberg, B., Juliusson, G. et al. (2000) P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia, J Clin Oncol18: 1837-1844.
87.
Villmann, C. and Becker, C.M. (2007) On the hypes and falls in neuroprotection: targeting the NMDA receptor, Neuroscientist13: 594-615.
88.
Wahlgren, N.G. and Ahmed, N. (2004) Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches, Cerebrovasc Dis17(Suppl. 1): 153-166.
89.
Wang, Y., Kilic, E., Kilic, U., Weber, B., Bassetti, C.L., Marti, H.H. and Hermann, D.M. (2005) VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena, Brain128: 52-63.
90.
Wartenberg, M., Ling, F.C., Muschen, M., Klein, F., Acker, H., Gassmann, M. et al. (2003) Regulation of the multidrug resistance transporter p-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species, FASEB J17: 503-505.
91.
Wenning, G.K., Colosimo, C., Geser, F. and Poewe, W. (2004) Multiple system atrophy, Lancet Neurol3: 93-103.
92.
Yan, N. and Shi, Y. (2005) Mechanisms of apoptosis through structural biology , Annu Rev Cell Dev Biol21: 35-56.
93.
Zhang, Z. and Chopp, M. (2002) Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia, Trends Cardiovasc Med12: 62-66.
94.
Zhang, Z.G., Zhang, L., Ding, G., Jiang, Q., Zhang, R.L., Zhang, X. et al. (2005) A model of mini-embolic stroke offers measurements of the neurovascular unit response in the living mouse, Stroke36: 2701-2704.
95.
Zhang, Z.G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C. et al. (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain, J Clin Invest106: 829-838.
96.
Zhu, H.J. and Liu, G.Q. (2004) Glutamate up-regulates p-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism , Life Sci75: 1313-1322.
